KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics. PMID 41350590 · Sci Rep · 2025-Dec-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease. PMID 41258994 · J Crohns Colitis · 2025-Dec-05 The record is from a Phase III randomized trial with a drug intervention and original results, but it is excluded because the condition (Crohn's disease) is not oncology, and the study does not have a primary/key time-to-event efficacy endpoint as required.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial. PMID 41207071 · Vaccine · 2025-Dec-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants. PMID 41187484 · Vaccine · 2025-Dec-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial. PMID 40998416 · Gut · 2025-Dec-05 The trial is a randomized, multicenter study in patients with malignant gastric outlet obstruction, which is oncology-related. It reports primary results of a randomized comparison. However, it is excluded because the intervention (endoscopic vs. surgical gastroenterostomy) is not a drug-containing intervention, and the primary endpoint is a composite clinical outcome measure, not a time-to-event efficacy endpoint like overall survival or progression-free survival. No Kaplan-Meier curves or hazard ratios are mentioned.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. PMID 41462987 · Biomedicines · 2025-Dec-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Surveillance After Extremity Tumor Surgery (SAFETY) Pilot International Multi-Center Randomized Controlled Trial. PMID 41440214 · Curr Oncol · 2025-Dec-04 This is an oncology, human, randomized pilot trial evaluating a non-drug intervention (surveillance frequency and imaging modality) for soft-tissue sarcoma. It lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The report describes feasibility and aggregate outcomes, not a definitive Phase III/IIIb trial with a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). PMID 41345848 · BMC Pulm Med · 2025-Dec-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes (MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial. PMID 41345697 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PERi-operative Selective Decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma. PMID 41345690 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma. PMID 41345095 · Blood Cancer J · 2025-Dec-04 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 5 Figure · 10 Panel · risk unclear
Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial. PMID 41344725 · Stroke Vasc Neurol · 2025-Dec-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Implementation evaluation of an evidence-informed hospital inpatient nursing framework (HIRAID® Inpatient): a protocol for a stepped-wedge cluster RCT. PMID 41339957 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. PMID 41337715 · N Engl J Med · 2025-Dec-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. PMID 40939190 · Blood · 2025-Dec-04 The record describes a Phase III trial with drug interventions and time-to-event endpoints, but it lacks explicit evidence of randomization (the abstract describes comparing outcomes based on different regimens chosen by local practice, not randomized assignment). Therefore, the required criterion of randomization is not met.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of short-term outcomes and oncological outcomes between totally laparoscopic distal gastrectomy and pylorus-preserving gastrectomy for early gastric cancer in the middle stomach: a non-inferiority randomised controlled trial. PMID 41482811 · Int J Surg · 2025-Dec-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Research waste among randomized clinical trials in endoscopic resection of gastrointestinal lesions: a cross-sectional study of ClinicalTrials.gov. PMID 41340094 · BMC Gastroenterol · 2025-Dec-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. PMID 41339350 · Nat Commun · 2025-Dec-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations. PMID 41339316 · Nat Commun · 2025-Dec-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 11 Panel · risk unclear
Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol. PMID 41339082 · Stroke Vasc Neurol · 2025-Dec-03 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial. PMID 41338637 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial. PMID 41338634 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of the index of consciousness 2 on intraoperative opioid dosage in ovarian cancer patients receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 41338618 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial. PMID 41335393 · J Robot Surg · 2025-Dec-03 The study is a randomized controlled trial in oncology (bladder cancer) with a primary efficacy endpoint, but the intervention is a comparison of surgical stapler devices (non-drug-only), and the primary endpoint (time to first flatus/bowel movement, POI rate, LOS) is not a time-to-event efficacy endpoint as defined (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU). PMID 41331921 · BMC Cancer · 2025-Dec-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of Anthelmintic Therapy for Invasive Helminth Infection on Microbial Translocation, Inflammation, and Immune Response among Ugandans Living with HIV: A Randomized Proof of Concept Study. PMID 41130223 · Am J Trop Med Hyg · 2025-Dec-03 The study is a randomized proof-of-concept trial evaluating anthelmintic therapy for helminth infection in people living with HIV. It is not a study of a human malignant neoplasm (cancer). Therefore, it does not meet the primary inclusion criterion of being an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma. PMID 40891733 · Jpn J Clin Oncol · 2025-Dec-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The outcome of injured cervical spinal cord with uncontrolled swelling under duraplasty: protocol of the ISCUD randomized controlled trial. PMID 41331929 · Trials · 2025-Dec-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial. PMID 41331725 · Stem Cell Res Ther · 2025-Dec-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Health Education on Cervical Cancer Screening Uptake and Knowledge among Target Women in Addis Ababa: A Randomized Controlled Trial. PMID 40878788 · Cancer Prev Res (Phila) · 2025-Dec-02 The study is a randomized controlled trial in oncology (cervical cancer prevention), but it is excluded because it lacks a drug-containing intervention (it uses health education), does not report a time-to-event efficacy endpoint (primary outcome is screening uptake proportion), and is not a definitive Phase III/IIIb trial (phase not specified).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial. PMID 40838592 · Am J Epidemiol · 2025-Dec-02 The record describes a methodological paper benchmarking an observational study against the BIG 1-98 randomized trial. While the referenced trial (BIG 1-98) was a Phase III RCT with drug intervention (letrozole vs. tamoxifen) and a time-to-event endpoint (risk of death), the provided abstract is not the original formal-result report of that trial. It is an observational analysis and benchmarking study. Therefore, it is not an eligible original result report of a clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial. PMID 41632122 · JAMA Netw Open · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Effectiveness of Acceptance and Commitment Therapy on Fear of Cancer Recurrence in Patients with Gastrointestinal Cancer with a Stoma: A Randomized Controlled Trial. PMID 41459871 · Asian Pac J Cancer Prev · 2025-Dec-01 The study is an oncology RCT with a psychological intervention, not a drug intervention, and does not report a time-to-event efficacy endpoint like OS/PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, and Immunogenicity of RSVpreF Vaccine in Pregnant Individuals Living with HIV. PMID 41441684 · Vaccines (Basel) · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial. PMID 41405883 · JAMA Netw Open · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial. PMID 41363834 · Cancer · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial. PMID 41359334 · JAMA Netw Open · 2025-Dec-01 The trial is oncology-focused, human, randomized, and reports original results. However, it is a feasibility/pilot study, not a definitive Phase III trial, and its intervention is a dietary program, not a drug. Furthermore, the study does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. PMID 41358945 · Oncologist · 2025-Dec-01 This is a retrospective observational study and review analyzing multiple prior drug approvals and trials, not an original report of a single randomized controlled trial. It does not present primary time-to-event efficacy results from a specific Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. PMID 41335575 · Hepatol Commun · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): A multicenter, randomized, double-blinded, placebo-controlled, phase III trial. PMID 41334635 · Chin Med J (Engl) · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age. PMID 41329145 · J Drugs Dermatol · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. PMID 41328764 · Cancer · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A contemporary examination of the effect of driver training for reducing crash risk in novice adolescent drivers: protocol for the DRIVER study, a random assignment trial. PMID 41327408 · Inj Epidemiol · 2025-Dec-01 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs. PMID 41327119 · BMC Cancer · 2025-Dec-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial. PMID 41320817 · Am J Psychiatry · 2025-Dec-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nemolizumab With Concomitant Topical Therapy in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis (ARCADIA 1 and ARCADIA 2): Results From Two Replicate, Double-Blind, Randomized Controlled Phase 3 Trials. PMID 41320020 · Pediatrics · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. PMID 41222953 · JAMA Cardiol · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome. PMID 41109533 · Eur J Pharm Sci · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. PMID 41100113 · JAMA Oncol · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. PMID 41082199 · JAMA Neurol · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -